Shots: Immunophotonics and CLS collaborate to evaluate the safety & tolerability of Immunophotonics’ IP-001 in P-Ib/IIa study for cancer patients with solid tumors The collaboration will combine CLS’ Immunostimulating Interstitial […]readmore
Tags : Agreement
Shots: Dr. Reddy’s to receive $70M upfront, $40.5M as milestones, an additional payment including existing contractual obligation and inventory with royalties on sales on a quarterly basis Upsher-Smith to get […]readmore
Shots: Genmab to receive $150M as option exercise fee, $125M as development milestones and 20% royalties on sales of HexaBody-CD38 till 2031, following 13-20% in future. Genmab to fund the […]readmore
Shots: Therapeutics MD to receive $15.82M upfront, $33.34M milestones including $2.26M as regulatory milestones & $31.08M as commercial milestones and royalties on sales in licensed territories Theramex to get exclusive […]readmore
Shots: Novartis to receive upfront from Sumitomo. Sumitomo to get rights to co-promote Novartis’ Equa and EquMet from July’19 in addition to distribution rights from Nov’19, receiving payment for promotion […]readmore
Shots: Bayer collaborates with Roche to develop & commercialize NGS-based companion diagnostics for multiple cancer therapies developed by Bayer and covers FMI’s complete portfolio of tests including its Foundation One […]readmore
Shots: NIH to receive $1.5M upfront, $16.3M as clinical, regulatory & commercial milestones including $3M prior to marketing approval in the US, Europe, Japan, Australia, China & India and $0.1M […]readmore
Shots: Bayer will utilize Sensible’s ReDS technology as a biomarker for monitoring lung congestion in a clinical study for patients with heart failure, making Bayer, Sensible’s largest customer in Europe […]readmore
Shots: Centrexion to receive $47.5M upfront, up to $950M as development, regulatory & commercial milestones and royalties on sales of product. Lilly to get exclusive WW rights for CNTX-0290 & […]readmore
Shots: Santhera enters into a collaboration with Biozentrum, University of Basel to explore the feasibility of the gene therapy by standard viral vectors for LAMA2 MD or MDC1A, co-financed by […]readmore